Key result
GLP-1 based therapies demonstrate potential to reduce ischaemia-reperfusion injury and improve functional recovery following myocardial ischaemia in preclinical and early clinical studies.
GLP-1 based therapies show potential as adjunctive treatments to minimize ischaemia-reperfusion injury during myocardial infarction, warranting further clinical investigation.
GLP-1 therapies merit randomized evaluation in myocardial infarction; should not alter current practice based on available evidence.
Coronary heart disease and type-2 diabetes are both major global health burdens associated with an increased risk of myocardial infarction (MI). Following MI, ischaemia-reperfusion injury (IRI) remains a significant contributor to myocardial injury at the cellular level. Research has focussed on identifying a strategy or intervention to minimise IRI to optimise reperfusion therapy, with the aim of delivering a superior clinical outcome. The incretin hormone glucagon-like peptide-1, already an established basis for the treatment of type-2 diabetes, also has the potential to protect against IRI. We explain the physiology and cellular processes involved in IRI, and the intracellular pathways activated by GLP-1, which could intercept IRI and deliver cardioprotection. The review also examines the current preclinical and clinical evidence for GLP-1 in cardioprotection and future directions for research as we look for an effective adjunctive treatment to minimise IRI.
No takes yet. Share an insight, caveat, or question.
Clarke et al. (2014) conducted a review in Myocardial ischaemia and ischaemia-reperfusion injury. Glucagon-like peptide-1 (GLP-1) was evaluated. GLP-1 based therapies demonstrate potential to reduce ischaemia-reperfusion injury and improve functional recovery following myocardial ischaemia in preclinical and early clinical studies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: